Most undervalued stock, page-23

If Admedus was Master Card ............

• Management sorted (albeit with new CEO to come) - tick
• Costs under control and falling - tick
• Revenue growing strongly and ahead of targets - tick
• Manufacturing issues resolved and improving - tick
• New products being launched - tick
• New geographies being approved - tick
• 12 months of strong news flow to come - tick
• Profitability 7 months away - tick
• Company sales culture in place and being bedded down - tick
• Company values established and being woven into company culture though existing staff and new hires - tick
• Marketing strategy revamped and targeted - tick
• Technology and IP world class - tick
• Legal issues resolved - tick
• Respected value investors starting to join the register - tick
• Old management and you know who selling down and nearly out - tick
• Capital position sound and sufficient to get us to profitability - tick
• Snowball effect in sales is imminent - increased target marketing x increased sales x increased products x increased cross selling x increased geographies = increased $$$$$$$ - tick
• Additional infusion contracts (or as WP described it "a plethora") to be announced - tick
• Collaboration with large multi national Pharma in Immuno Oncology (yet to be named) - tick
• The start of HPV phase 1b trials for head and neck cancers imminent - tick

• AHZ share price yet to reflect all of the above and yes (IMHO) currently undervalued - tick

• Immunotherapies blue sky potential alive and well - Priceless ..........................

All the ducks are lined up in a row. Now for a champion CEO to drive this Ferrari and set a new track record.

(All just in my opinion and judgement - DYOR and not advice) Exciting times ahead.